Nature Communications (Feb 2020)
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
- Katrin Aslan,
- Verena Turco,
- Jens Blobner,
- Jana K. Sonner,
- Anna Rita Liuzzi,
- Nicolás Gonzalo Núñez,
- Donatella De Feo,
- Philipp Kickingereder,
- Manuel Fischer,
- Ed Green,
- Ahmed Sadik,
- Mirco Friedrich,
- Khwab Sanghvi,
- Michael Kilian,
- Frederik Cichon,
- Lara Wolf,
- Kristine Jähne,
- Anna von Landenberg,
- Lukas Bunse,
- Felix Sahm,
- Daniel Schrimpf,
- Jochen Meyer,
- Allen Alexander,
- Gianluca Brugnara,
- Ralph Röth,
- Kira Pfleiderer,
- Beate Niesler,
- Andreas von Deimling,
- Christiane Opitz,
- Michael O. Breckwoldt,
- Sabine Heiland,
- Martin Bendszus,
- Wolfgang Wick,
- Burkhard Becher,
- Michael Platten
Affiliations
- Katrin Aslan
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Verena Turco
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Jens Blobner
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Jana K. Sonner
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Anna Rita Liuzzi
- Institute of Experimental Immunology, University of Zurich
- Nicolás Gonzalo Núñez
- Institute of Experimental Immunology, University of Zurich
- Donatella De Feo
- Institute of Experimental Immunology, University of Zurich
- Philipp Kickingereder
- Department of Neuroradiology, Heidelberg University Medical Center
- Manuel Fischer
- Department of Neuroradiology, Heidelberg University Medical Center
- Ed Green
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Ahmed Sadik
- Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ)
- Mirco Friedrich
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Khwab Sanghvi
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Michael Kilian
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Frederik Cichon
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Lara Wolf
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Kristine Jähne
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Anna von Landenberg
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Lukas Bunse
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Felix Sahm
- DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
- Daniel Schrimpf
- DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
- Jochen Meyer
- DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
- Allen Alexander
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Gianluca Brugnara
- Department of Neuroradiology, Heidelberg University Medical Center
- Ralph Röth
- nCounter Core Facility, Institute of Human Genetics, University of Heidelberg
- Kira Pfleiderer
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Beate Niesler
- nCounter Core Facility, Institute of Human Genetics, University of Heidelberg
- Andreas von Deimling
- DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
- Christiane Opitz
- Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ)
- Michael O. Breckwoldt
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- Sabine Heiland
- Department of Neuroradiology, Heidelberg University Medical Center
- Martin Bendszus
- Department of Neuroradiology, Heidelberg University Medical Center
- Wolfgang Wick
- Department of Neurology, Heidelberg University Medical Center
- Burkhard Becher
- Institute of Experimental Immunology, University of Zurich
- Michael Platten
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ)
- DOI
- https://doi.org/10.1038/s41467-020-14642-0
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Modeling patient-individual resistance to immunotherapy is challenging. Here, the authors use a syngeneic experimental hypermutated orthotopic glioma model to define radiological and biological features that can predict or explain the mechanistic differences between responders and non-responders to immunotherapy.
